Logo
N

Novocure

1399 employees

We are a global oncology company working to extend survival in some of the most aggressive forms of cancer through the development and commercialization of our innovative therapy, Tumor Treating Fields. Our commercialized products are approved in certain countries for the treatment of adult patients with glioblastoma and in the U.S. for the treatment of adult patients with malignant pleural mesothelioma. We have ongoing or completed clinical trials investigating Tumor Treating Fields in brain metastases, non-small cell lung cancer, pancreatic cancer, ovarian cancer, liver cancer and gastric cancer. Headquartered in Switzerland, Novocure has U.S. operations in Portsmouth, New Hampshire and Chesterbrook, Pennsylvania. Additionally, Novocure has offices in Canada, Germany, Japan, Poland and Israel.

Investor insights

Funding rounds participated in

$100M sweet spot round size

Investor type

Public Company

Basic info

Industry

Medical Equipment Manufacturing

Sectors

Medical Equipment Manufacturing

Date founded

2000

Funding rounds raised

Total raised

$100M

from 1 investors over 1 rounds

N

Novocure raised $100M on June 2, 2024

Investors: Pharmakon Advisors

FAQ